Clinical trial of Siddha medicine MV Kashayam (Internally) for the management and treatment of COVID 19 patients

A prospective single center randomized double arm, open labeled comparative clinical trial to evaluate the effectiveness of Siddha medicine MV Kashayam VS standard conventional treatment among RT-PCR positive COVID 19 patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/02/040365

Enrollment

200

Registered

2022-02-17

Start date

Unknown

Completion date

Unknown

Last updated

2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 3: U071- COVID 19 virus identified

Interventions

Intervention1: MV Kashayam: The kashayam has prepared with mutiple herbs combination and study its efficacy in curing the COVID 19 patients with mild and moderate condition at the dose rate of 150 ml

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patient positive with Rt PCR test 2 The age group of 15 to 60 years 3 Patients with mild and moderate symptoms of COVID 19 4 Patients of both sexes and willing to accept the treatment method

Exclusion criteria

Exclusion criteria: 1 RT PCR negative patients 2 Patients less than 15 years of age and above 60 years of age 3 Pregnant and breastfeeding women 4 Patients with severe COVID 19 symptoms 5 Patients with other systemic malignant diseases such as malignant tumors, mental illness etc., which the researchers consider unsuitable for participation in the study 6 Allopathic antiviral treatment patients. 7 Not willing to continue the treatment 8. Patient discharge against medical advice 9 Patients participating in other clinical trails

Design outcomes

Primary

Measure	Time frame
RT PCR negative and or symptomatic reduction in the patientsTimepoint: RT PCR negative and or symptomatic reduction in the patients within 14 days of first swab taken.	—

Secondary

Measure	Time frame
Even after Length of stay in hospitalization following patients were consider to have poor out come even then duration of hospital stay is less. Patients referred to higher center. Patients who were dead after receiving five days of our treatment.For following patients with less duration of hospital stay are consider to have good out come were discharged and referred to COVID care center or home isolation under supervision.Timepoint: 4 to 10 days	—

Measure

Time frame

Even after Length of stay in hospitalization following patients were consider to have poor out come even then duration of hospital stay is less. Patients referred to higher center. Patients who were dead after receiving five days of our treatment.For following patients with less duration of hospital stay are consider to have good out come were discharged and referred to COVID care center or home isolation under supervision.Timepoint: 4 to 10 days

—

Countries

India

Contacts

Public ContactDr P Dharumarajan

Government Hospital Aruppukottai

malarkannan@aactni.edu.in9442355686

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026